HDAC6 as a target for neurodegenerative diseases: What makes it different from the other HDACs?

Molecular Neurodegeneration

Volumn 8, Issue 1, 2013, Pages

  Simões Pires, Claudia ^a   Zwick, Vincent ^a   Nurisso, Alessandra ^a   Schenker, Esther ^b   Carrupt, Pierre Alain ^a   Cuendet, Muriel ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

HDAC6; Histone deacetylase; Neurodegenerative diseases

Indexed keywords

ACETAMIDE DERIVATIVE; ALPHA SYNUCLEIN; ALPHA TUBULIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK TRANSCRIPTION FACTOR 1; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; ISOENZYME; KINESIN 1; UNCLASSIFIED DRUG; WT 161;

ALZHEIMER DISEASE; BRAIN MITOCHONDRION; BRAIN REGION; CELLULAR DISTRIBUTION; COGNITION; COMPUTER MODEL; DEGENERATIVE DISEASE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME REGULATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; EPIGENETICS; GENE SILENCING; HUMAN; HUNTINGTON CHOREA; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR TRANSPORT; NERVE CELL NECROSIS; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW;

ANIMALS; HISTONE DEACETYLASES; HUMANS; NEURODEGENERATIVE DISEASES;

ANIMALIA;

EID: 84872982286     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-8-7     Document Type: Review

References (121)

1. Histone deacetylase inhibitors: molecular mechanisms of action. Xu WS, Parmigiani RB, Marks PA, Oncogene 2007 26 5541 5552 10.1038/sj.onc.1210620 17694093
2. Histone deacetylases as transducers and targets of nuclear signaling. Walkinshaw DR, Tahmasebi S, Bertos NR, Yang XJ, J Cell Biochem 2008 104 1541 1552 10.1002/jcb.21746 18425769
3. Unraveling the hidden catalytic activity of vertebrate class Ila histone deacetylases. Lahm A, Paolini C, Pallaoro M, Nardi M, Jones P, Neddermann P, Sambucini S, Bottomley M, Lo Surdo P, Carfi A, et al. Proc Natl Acad Sci USA 2007 104 17335 17340 10.1073/pnas.0706487104 17956988
4. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Boyault C, Zhang Y, Fritah S, Caron C, Gilquin B, Kwon SH, Garrido C, Yao TP, Vourc'h C, Matthias P, et al. Genes Dev 2007 21 2172 2181 10.1101/gad.436407 17785525
5. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Haberland M, Montgomery RL, Olson EN, Nat Rev Genet 2009 10 32 42 10.1038/nrg2485 19065135
6. HDAC inhibitors and neurodegeneration: at the edge between protection and damage. Dietz KC, Casaccia P, Pharmacol Res 2010 62 11 17 10.1016/j.phrs.2010. 01.011 20123018
7. Histone deacetylase inhibitors: overview and perspectives. Dokmanovic M, Clarke C, Marks PA, Mol Cancer Res 2007 5 981 989 10.1158/1541-7786.MCR-07-0324 17951399
8. Histone deacetylases (HDACs): characterization of the classical HDAC family. De Ruijter AJM, van Gennip AH, Caron HN, Kemp S, Van Kuilenburg ABP, Biochem J 2003 370 737 749 10.1042/BJ20021321 12429021
9. Targeting the correct HDAC(s) to treat cognitive disorders. Fischer A, Sananbenesi F, Mungenast A, Tsai LH, Trends Pharmacol Sci 2010 31 605 617 10.1016/j.tips.2010.09.003 20980063
10. Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. Mai A, Massa S, Pezzi R, Simeoni S, Rotili D, Nebbioso A, Scognamiglio A, Altucci L, Loidl P, Brosch G, J Med Assoc Thai 2005 48 3344 3353
11. Distribution of histone deacetylases 1-11 in the rat brain. Broide RS, Redwine JM, Aftahi N, Young W, Bloom FE, Winrow CJ, J Mol Neurosc 2007 31 47 58 10.1007/BF02686117
12. Functional significance of histone deacetylase diversity. Khochbin S, Verdel A, Lemercier C, Seigneurin-Berny D, Curr Opin Genet Dev 2001 11 162 166 10.1016/S0959-437X(00)00174-X 11250139
13. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. Gao L, Cueto MA, Asselbergs F, Atadja P, J Biol Chem 2002 277 25748 25755 10.1074/jbc.M111871200 11948178
14. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Saha RN, Pahan K, Cell Death Differ 2005 13 539 550
15. Tuning acetylation levels with HAT activators: therapeutic strategy in neurodegenerative diseases. Selvi BR, Cassel JC, Kundu TK, Boutillier AL, Biochim Biophys Acta 2010 1799 840 853 10.1016/j.bbagrm.2010.08.012 20833281
16. Putting the "HATI" back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditions. Sleiman SF, Basso M, Mahishi L, Kozikowski AP, Donohoe ME, Langley B, Ratan RR, Expert Opin Inv Drugs 2009 18 573 584 10.1517/13543780902810345
17. Targeting Huntington's disease through histone deacetylases. Gray S, Clin Epigen 2011 2 257 277 10.1007/s13148-011-0025-7
18. Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation. Tang H, Wang XS, Huang XP, Roth BL, Butler KV, Kozikowski AP, Jung M, Tropsha A, J Chem Inf Model 2009 49 461 476 10.1021/ci800366f 19182860
19. HDAC6 α-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases. Li G, Jiang H, Chang M, Xie H, Hu L, J Neurol Sci 2011 304 1 8 10.1016/j.jns.2011.02.017 21377170
20. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP, Nature 1999 401 188 193 10.1038/43710 10490031
21. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. Wang DF, Helquist P, Wiech NL, Wiest O, J Med Chem 2005 48 6936 6947 10.1021/jm0505011 16250652
22. Computational studies on the histone deacetylases and the design of selective histone deacetylase inhibitors. Wang D, Curr Topics Med Chem 2009 9 241 256 10.2174/156802609788085287
23. Crystal structure of the quorum-sensing protein TraM and its interaction with the transcriptional regulator TraR. Vannini A, Volpari C, Di Marco S, J Biol Chem 2004 279 24291 24296 10.1074/jbc.M401855200 15044488
24. Role of histone acetylation in cell physiology and diseases: an update. Khan SN, Khan AU, Clin Chim Acta 2010 411 1401 1411 10.1016/j.cca.2010.06.020 20598676
25. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. Gregoretti IV, Lee YM, Goodson HV, J Mol Biol 2004 338 17 31 10.1016/j.jmb.2004.02.006 15050820
26. Inside HDAC with HDAC inhibitors. Bertrand P, Eur J Med Chem 2010 45 2095 2116 10.1016/j.ejmech.2010.02.030 20223566
27. HDAC family: what are the cancer relevant targets? Witt O, Deubzer HE, Milde T, Oehme I, Cancer Lett 2009 277 8 21 10.1016/j.canlet.2008.08.016 18824292
28. Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. Schuetz A, Min J, Allali-Hassani A, Schapira M, Shuen M, Loppnau P, Mazitschek R, Kwiatkowski NP, Lewis TA, Maglathin RL, et al. J Biol Chem 2008 283 11355 11363 10.1074/jbc.M707362200 18285338
29. Protein aggregates are recruited to aggresome by histone deacetylase 6 via unanchored ubiquitin C termini. Ouyang H, Ali YO, Ravichandran M, Dong A, Qiu W, MacKenzie F, Dhe-Paganon S, Arrowsmith CH, Zhai RG, J Biol Chem 2012 287 2317 2327 10.1074/jbc.M111.273730 22069321
30. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-Carter R, et al. J Neurosci 2003 23 9418 9427 14561870
31. Role of the tetradecapeptide repeat domain of human histone deacetylase 6 in cytoplasmic retention. Bertos NR, Gilquin B, Chan GKT, Yen TJ, Khochbin S, Yang XJ, J Biol Chem 2004 279 48246 48254 10.1074/jbc.M408583200 15347674
32. Histone deacetylase 6 interacts with the microtubule-associated protein tau. Ding H, Dolan PJ, Johnson GVW, J Neurochem 2008 106 2119 2130 10.1111/j.1471-4159.2008.05564.x 18636984
33. Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZ domain) and copurifies with deubiquitinating enzymes. Hook SS, Orian A, Cowley SM, Eisenman RN, Proc Natl Acad Sci USA 2002 99 13425 13430 10.1073/pnas. 172511699 12354939
34. Solution structure of the Ubp-M BUZ domain, a highly specific protein module that recognizes the C-terminal tail of free ubiquitin. Pai MT, Tzeng SR, Kovacs JJ, Keaton MA, Li SSC, Yao TP, Zhou P, J Mol Biol 2007 370 290 302 10.1016/j.jmb.2007.04.015 17512543
35. The ubiquitin binding domain ZnF UBP recognizes the C-terminal diglycine motif of unanchored ubiquitin. Reyes-Turcu FE, Horton JR, Mullally JE, Heroux A, Cheng X, Wilkinson KD, Cell 2006 124 1197 1208 10.1016/j.cell.2006.02.038 16564012
36. Strategies in developing promising histone deacetylase inhibitors. Zhang L, Fang H, Xu W, Med Res Rev 2010 30 585 602 10.1002/med.20169 19634125
37. Structural origin of selectivity in class II-selective histone deacetylase inhibitors. Estiu G, Greenberg E, Harrison CB, Kwiatkowski NP, Mazitschek R, Bradner JE, Wiest O, J Med Chem 2008 51 2898 2906 10.1021/jm7015254 18412327
38. Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression. Charrier C, Clarhaut J, Gesson JP, Estiu G, Wiest O, Roche J, Bertrand P, J Med Chem 2009 52 3112 3115 10.1021/jm9002439 19385600
39. Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. Kozikowski AP, Tapadar S, Luchini DN, Kim KH, Billadeau DD, J Med Chem 2008 51 4370 4373 10.1021/jm8002894 18642892
40. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. Butler KV, Kalin J, Brochier C, Vistoli G, Langley B, Kozikowski AP, J Am Chem Soc 2010 132 10842 10846 10.1021/ja102758v 20614936
41. Pyridylalanine-containing hydroxamic acids as selective HDAC6 inhibitors. Schäfer S, Saunders L, Schlimme S, Valkov V, Wagner J, Kratz F, Sippl W, Verdin E, Jung M, Chem Med Chem 2009 4 283 290 19090524
42. Histone deacetylase cytoplasmic trapping by a novel fluorescent HDAC inhibitor. Kong Y, Jung M, Wang K, Grindrod S, Velena A, Lee SA, Dakshanamurthy S, Yang Y, Miessau M, Zheng C, et al. Mol Cancer Ther 2011 10 1591 1599 10.1158/1535-7163.MCT-10-0779 21697394
43. Carbamate prodrug concept for hydroxamate HDAC inhibitors. Schlimme S, Hauser AT, Carafa V, Heinke R, Kannan S, Stolfa DA, Cellamare S, Carotti A, Altucci L, Jung M, et al. Chem Med Chem 2011 6 1193 1198 21416613
44. Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs). Schäfer S, Saunders L, Eliseeva E, Velena A, Jung M, Schwienhorst A, Strasser A, Dickmanns A, Ficner R, Schlimme S, et al. Bioorg Med Chem 2008 16 2011 2033 10.1016/j.bmc.2007.10.092 18054239
45. Characterization of the two catalytic domains in histone deacetylase 6. Zou H, Wu Y, Navre M, Sang BC, Biochem Biophys Res Commun 2006 341 45 50 10.1016/j.bbrc.2005.12.144 16412385
46. Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB: CBP-dependent transcriptional activation. Vecsey CG, Hawk JD, Lattal KM, Stein JM, Fabian SA, Attner MA, Cabrera SM, McDonough CB, Brindle PK, Abel T, et al. J Neurosci 2007 27 6128 6140 10.1523/JNEUROSCI.0296-07.2007 17553985
47. Recovery of learning and memory is associated with chromatin remodelling. Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai LH, Nature 2007 447 178 182 10.1038/nature05772 17468743
48. Enriched environments, experience-dependent plasticity and disorders of the nervous system. Nithianantharajah J, Hannan AJ, Nat Rev Neurosci 2006 7 697 709 10.1038/nrn1970 16924259
49. Altered histone acetylation is associated with age-dependent memory impairment in mice. Peleg S, Sananbenesi F, Zovoilis A, Burkhardt S, Bahari-Javan S, Agis-Balboa RC, Cota P, Wittnam JL, Gogol-Doering A, Opitz L, et al. Science 2010 328 753 756 10.1126/science.1186088 20448184
50. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH, Nature 1999 402 615 622 10.1038/45159 10604467
51. Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity. Kim D, Frank CL, Dobbin MM, Tsunemoto RK, Tu W, Peng PL, Guan JS, Lee BH, Moy LY, Giusti P, et al. Neuron 2008 60 803 817 10.1016/j.neuron.2008.10.015 19081376
52. HDAC2 negatively regulates memory formation and synaptic plasticity. Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, Nieland TJF, Zhou Y, Wang X, Mazitschek R, et al. Nature 2009 459 55 60 10.1038/nature07925 19424149
53. Post-training intrahippocampal inhibition of class I histone deacetylases enhances long-term object-location memory. Hawk JD, Florian C, Abel T, Learn Mem 2011 18 367 370 10.1101/lm.2097411 21576516
54. HDAC3 is a critical negative regulator of long-term memory formation. McQuown SC, Barrett RM, Matheos DP, Post RJ, Rogge GA, Alenghat T, Mullican SE, Jones S, Rusche JR, Lazar MA, et al. J Neurosci 2011 31 764 774 10.1523/JNEUROSCI.5052-10.2011 21228185
55. Selective toxicity by HDAC3 in neurons: regulation by Akt and GSK3β Bardai FH, D'Mello SR, J Neurosci 2011 31 1746 1751 10.1523/JNEUROSCI.5704-10. 2011 21289184
56. Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Yang XJ, Grégoire S, Mol Cell Biol 2005 25 2873 2884 10.1128/MCB.25.8.2873-2884.2005 15798178
57. Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death. Bolger TA, Yao TP, J Neurosci 2005 25 9544 9553 10.1523/JNEUROSCI. 1826-05.2005 16221865
58. HDAC4 regulates neuronal survival in normal and diseased retinas. Chen B, Cepko CL, Science 2009 323 256 259 10.1126/science.1166226 19131628
59. Intracellular trafficking of histone deacetylase 4 regulates long-term memory formation. Wang WH, Cheng LC, Pan FY, Xue B, Wang DY, Chen Z, Li CJ, Anatom Rec 2011 294 1025 1034 10.1002/ar.21389
60. Histone deacetylases 1 and 2 form a developmental switch that controls excitatory synapse maturation and function. Akhtar MW, Raingo J, Nelson ED, Montgomery RL, Olson EN, Kavalali ET, Monteggia LM, J Neurosci 2009 29 8288 8297 10.1523/JNEUROSCI.0097-09.2009 19553468
61. HDAC1 in axonal degeneration: a matter of subcellular localization. Kim JY, Casaccia P, Cell Cycle 2010 9 3680 3684 20930523
62. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, et al. Biochem J 2008 409 581 589 10.1042/BJ20070779 17868033
63. Direct binding with histone deacetylase 6 mediates the reversible recruitment of parkin to the centrosome. Jiang Q, Ren Y, Feng J, J Neurosci 2008 28 12993 13002 10.1523/JNEUROSCI.2860-08.2008 19036992
64. HDAC6 regulates aggresome-autophagy degradation pathway of α-synuclein in response to MPP+-induced stress. Su M, Shi JJ, Yang YP, Li J, Zhang YL, Chen J, Hu LF, Liu CF, J Neurochem 2011 117 112 120 10.1111/j.1471-4159.2011.07180.x 21235576
65. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. Dompierre JP, Godin JD, Charrin BC, Cordelieres FP, King SJ, Humbert S, Saudou F, J Neurosci 2007 27 3571 3583 10.1523/JNEUROSCI.0037-07.2007 17392473
66. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. Iwata A, Riley BE, Johnston JA, Kopito RR, J Biol Chem 2005 280 40282 40292 10.1074/jbc.M508786200 16192271
67. HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Parmigiani R, Xu W, Venta-Perez G, Erdjument-Bromage H, Yaneva M, Tempst P, Marks P, Proc Natl Acad Sci USA 2008 105 9633 9638 10.1073/pnas.0803749105 18606987
68. HDAC6 regulates mitochondrial transport in hippocampal neurons. Chen S, Owens GC, Makarenkova H, Edelman DB, PLoS One 2010 5 10848 10.1371/journal.pone. 0010848 20520769
69. Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies. Kozikowski AP, Chen Y, Gaysin A, Chen B, D'Annibale MA, Suto CM, Langley BC, J Med Chem 2007 50 3054 3061 10.1021/jm070178x 17539623
70. Subtype selective substrates for histone deacetylases. Heltweg B, Dequiedt F, Marshall BL, Brauch C, Yoshida M, Nishino N, Verdin E, Jung M, J Med Chem 2004 47 5235 5243 10.1021/jm0497592 15456267
71. Induction of clusterin/apoJ expression by histone deacetylase inhibitors in neural cells. Nuutinen T, Suuronen T, Kyrylenko S, Huuskonen J, Salminen A, Neurochem Int 2005 47 528 538 10.1016/j.neuint.2005.07.007 16157419
72. Molecular chaperones in the cytosol: from nascent chain to folded protein. Hartl FU, Hayer-Hartl M, Science 2002 295 1852 1858 10.1126/science.1068408 11884745
73. Autophagy gone away in neurodegenerative diseases. Wong E, Cuervo AM, Nat Neurosci 2010 13 805 811 10.1038/nn.2575 20581817
74. The ubiquitin proteasome system in neurodegenerative diseases: Sometimes the chicken, sometimes the egg. Ciechanover A, Brundin P, Neuron 2003 40 427 446 10.1016/S0896-6273(03)00606-8 14556719
75. The role of heat shock proteins during neurodegeneration in Alzheimer's, Parkinson's and Huntington's disease. Wyttenbach A, Arrigo AP, Heat Shock Proteins in Neural Cells Landes Bioscience, Austin, Richter-Landsberg C, 2006
76. The proteasome: a suitable antineoplastic target. Adams J, Nat Rev Canc 2004 4 349 360 10.1038/nrc1361
77. The ubiquitin pathway: an emerging drug target in cancer therapy. Ande SR, Chen J, Maddika S, Eur J Pharmacol 2009 625 199 205 10.1016/j.ejphar.2009. 08.042 19835866
78. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Bennett EJ, Bence NF, Jayakumar R, Kopito RR, Mol Cell 2005 17 351 365 10.1016/j.molcel. 2004.12.021 15694337
79. Toxic proteins in neurodegenerative disease. Taylor JP, Hardy J, Fischbeck KH, Science 2002 296 1991 1995 10.1126/science.1067122 12065827
80. Ubiquitin is a common factor in intermediate filament inclusion-bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibers in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver-disease. Lowe J, Blanchard A, Morrell K, Lennox G, Reynolds L, Billett M, Landon M, Mayer RJ, J Pathol 1988 155 9 15 10.1002/path.1711550105 2837558
81. Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease. Dickson DW, Schmidt ML, Lee VMY, Zhao ML, Yen SH, Trojanowski JQ, Acta Neuropathol 1994 87 269 276 10.1007/BF00296742 7912027
82. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP, Cell 1997 90 537 548 10.1016/S0092-8674(00)80513-9 9267033
83. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Perry G, Friedman R, Shaw G, Chau V, Proc Natl Acad Sci USA 1987 84 3033 3036 10.1073/pnas.84.9.3033 3033674
84. Proteasomal inhibition by α-synuclein filaments and oligomers. Lindersson E, Beedholm R, Hojrup P, Moos T, Gai WP, Hendil KB, Jensen PH, J Biol Chem 2004 279 12924 12934 14711827
85. Role of the ubiquitin proteasome system in Parkinson's disease. Lim KL, Tan J, BMC Biochem 2007 8 13 10.1186/1471-2091-8-S1-S13 18047737
86. Impairment of the ubiquitin-proteasome system by protein aggregation. Bence NF, Sampat RM, Kopito RR, Science 2001 292 1552 1555 10.1126/science.292. 5521.1552 11375494
87. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. Keck S, Nitsch R, Grune T, Ullrich O, J Neurochem 2003 85 115 122 10.1046/j.1471-4159.2003.01642.x 12641733
88. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP, Cell 2003 115 727 738 10.1016/S0092-8674(03)00939-5 14675537
89. Identification of components of the murine histone deacetylase 6 complex: link between acetylation and ubiquitination signaling pathways. Seigneurin-Berny D, Verdel A, Curtet S, Lemercier C, Garin J, Rousseaux S, Khochbin S, Mol Cell Biol 2001 21 8035 8044 10.1128/MCB.21.23.8035-8044.2001 11689694
90. Complete structure of p97/valosin-containing protein reveals communication between nucleotide domains. DeLaBarre B, Brunger AT, Nat Struct Mol Biol 2003 10 856 863 10.1038/nsb972
91. The heavy metal cadmium induces valosin-containing protein (VCP)-mediated aggresome formation. Song C, Xiao Z, Nagashima K, Li CC, Lockett SJ, Dai RM, Cho EH, Conrads TP, Veenstra TD, Colburn NH, et al. Toxicol Appl Pharmacol 2008 228 351 363 10.1016/j.taap.2007.12.026 18261755
92. HDAC6-p97/VCP controlled polyubiquitin chain turnover. Boyault C, Gilquin B, Zhang Y, Rybin V, Garman E, Meyer-Klaucke W, Matthias P, Muller CW, Khochbin S, EMBO J 2006 25 3357 3366 10.1038/sj.emboj.7601210 16810319
93. To prevent neurodegeneration: HDAC6 uses different strategies for different challenges. Du G, Jiao R, Commun Integr Biol 2011 4 139 142 10.4161/cib.4.2.14272 21655425
94. The ubiquitin-like modifier FAT10 interacts with HDAC6 and localizes to aggresomes under proteasome inhibition. Kalveram B, Schmidtke G, Groettrup M, J Cell Sci 2008 121 4079 4088 10.1242/jcs.035006 19033385
95. Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation. Cook C, Gendron TF, Scheffel K, Carlomagno Y, Dunmore J, DeTure M, Petrucelli L, Human Mol Gen 2012 21 2936 2945 10.1093/hmg/dds125
96. HDAC6 is a target for protection and regeneration following injury in the nervous system. Rivieccio MA, Brochier C, Willis DE, Walker BA, D'Annibale MA, McLaughlin K, Siddiq A, Kozikowski AP, Jaffrey SR, Twiss JL, et al. Proc Natl Acad Sci USA 2009 106 19599 19604 10.1073/pnas.0907935106 19884510
97. Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6. Olzmann JA, Li L, Chudaev MV, Chen J, Perez FA, Palmiter RD, Chin LS, J Cell Biol 2007 178 1025 1038 10.1083/jcb.200611128 17846173
98. Neuronal apoptosis induced by histone deacetylase inhibitors. Salminen A, Tapiola T, Korhonen P, Suuronen T, Mol Brain Res 1998 61 203 206 10.1016/S0169-328X(98)00210-1 9795219
99. Increased level of active GSK-3β in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Leroy K, Yilmaz Z, Brion JP, Neuropathol Appl Neurobiol 2007 33 43 55 17239007
100. The Consortium to Establish a Registry for Alzheimers's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimers's disease. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, Vanbelle G, Berg L, Neurology 1991 41 479 486 10.1212/WNL.41.4.479 2011243
101. Critical role of the hippocampus in memory for sequences of events. Fortin NJ, Agster KL, Eichenbaum HB, Nat Neurosci 2002 5 458 462 11976705
102. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, Lebert F, Pasquier F, David JP, Neurology 2002 59 398 407 10.1212/WNL.59.3.398 12177374
103. Tau-an inhibitor of deacetylase HDAC6 function. Perez M, Santa-Maria I, De Barreda EG, Zhu X, Cuadros R, Cabrero JR, Sanchez-Madrid F, Dawson HN, Vitek MP, Perry G, et al. J Neurochem 2009 109 1756 1766 10.1111/j.1471-4159.2009. 06102.x 19457097
104. Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease. Govindarajan N, Rao P, Burkhardt S, Sananbenesi F, Schlüter OM, Bradke F, Lu J, Fischer A, EMBO Mol Med 2012 5 52 63 23184605
105. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Xu J, Kao SY, Lee FJS, Song WH, Jin LW, Yankner BA, Nature Med 2002 8 600 606 10.1038/nm0602-600 12042811
106. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Zarow C, Lyness SA, Mortimer JA, Chui HC, Arch Neurol 2003 60 337 341 10.1001/archneur.60.3.337 12633144
107. A role for α-synuclein in the regulation of dopamine biosynthesis. Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, Zigmond MJ, J Neurosci 2002 22 3090 3099 11943812
108. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L, Science 2000 287 1265 1269 10.1126/science.287.5456.1265 10678833
109. α-Synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, Liu K, Xu K, Strathearn KE, Liu F, et al. Science 2006 313 324 328 10.1126/science.1129462 16794039
110. Drosophila histone deacetylase 6 protects dopaminergic neurons against α-synuclein toxicity by promoting inclusion formation. Du G, Liu X, Chen X, Song M, Yan Y, Jiao R, Wang C, Mol Biol Cell 2010 21 2128 2137 10.1091/mbc.E10-03-0200 20444973
111. Diagnosis and treatment of Parkinson disease: molecules to medicine. Savitt JM, Dawson VL, Dawson TM, J Clin Invest 2006 116 1744 1754 10.1172/JCI29178 16823471
112. Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy. Lee JY, Nagano Y, Taylor JP, Lim KL, Yao TP, J Cell Biol 2010 189 671 679 10.1083/jcb.201001039 20457763
113. Altered transcription in yeast expressing expanded polyglutamine. Hughes RE, Lo RS, Davis C, Strand AD, Neal CL, Olson JM, Fields S, Proc Natl Acad Sci USA 2001 98 13201 13206 10.1073/pnas.191498198 11687606
114. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB, Ren SR, Li XJ, Albin RL, Detloff PJ, Human Mol Gen 2001 10 137 144 10.1093/hmg/10.2.137
115. Disruption of axonal transport by loss of huntingtin or expression of pathogenic PolyQ proteins in Drosophila. Gunawardena S, Her LS, Brusch RG, Laymon RA, Niesman IR, Gordesky-Gold B, Sintasath L, Bonini NM, Goldstein LSB, Neuron 2003 40 25 40 10.1016/S0896-6273(03)00594-4 14527431
116. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, Kubilus JK, Ryu H, Langley B, Ratan RR, Ferrante RJ, et al. J Biol Chem 2005 280 556 563 15494404
117. Chaperoning brain degeneration. Bonini NM, Proc Natl Acad Sci USA 2002 99 16407 16411 10.1073/pnas.152330499 12149445
118. Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease. Bobrowska A, Paganetti P, Matthias P, Bates GP, PLoS One 2011 6 20696 10.1371/journal.pone. 0020696 21677773
119. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. D'Ydewalle C, Krishnan J, Chiheb DM, Van Damme P, Irobi J, Kozikowski AP, Vanden Berghe P, Timmerman V, Robberecht W, Van Den Bosch L, Nat Med 2011 17 968 974 10.1038/nm.2396 21785432
120. Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6. Fiesel FC, Voigt A, Weber SS, Van den Haute C, Waldenmaier A, Gorner K, Walter M, Anderson ML, Kern JV, Rasse TM, et al. EMBO J 2010 29 209 221 10.1038/emboj.2009.324 19910924
121. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Wells JA, McClendon CL, Nature 2007 450 1001 1009 10.1038/nature06526 18075579